Table 1.

Characteristics of studies included in the analysis

Study (Year)PublicationCohort DescriptionaNTreatment Period (weeks)DialysisTarget Hb/HctHemoglobin, mean g/dl (SD)SBP, mean mmHg (SD)DBP, mean mmHg (SD)LVMi, mean gm/m2 (SD)Δ LVMi
BaselineFinalBaselineFinalBaselineFinalBaselineFinal
Cannella (1990)Clin NephrolTreated926Y10 g/dl5.9 (1.30)10.2 (1.30)115 (17)112 (19)70 (5)73 (14)115 (17)78 (14)−37
Pascual (1991)Clin Nephrol(i) Hypertensive852Y30-35%159 (7)145 (12)96 (8)87 (9)235 (40)168 (51)−67.2
(ii) Normotensive752Y30-35%6.4 (0.90)10.5 (0.90)133 (10)122 (11)82 (10)75 (9)183 (43)107 (24)−75.8
Portoles (1997)Kidney IntTreated1126N35%9 (1.0)11.7 (1.30)144 (32.5)147.2 (31.2)76.0 (20.90)81.1 (15.3)178 (68)147 (68)−30.9
Massimetti (1998)Blood PurifTreated1165Y30-35%8.4 (0.80)10.9 (1.20)155 (12)154 (24)87 (7)85 (9)186 (56)189 (39)3
Foley (2000)Kidney Int(i) CLVH / Lower Hb3648Y9.5-10.5 g/dl10.1 (0.60)10.5 (1.20)157 (11.8)NA81 (8.9)NA139 (25)145.1 (NA)6.1
(ii) CLVH / Higher Hb3448Y13-14 g/dl10.0 (0.90)12.8 (1.10)162 (12.9)NA82 (7.2)NA147 (26)148.1 (NA)1.1
(iii) LVD / Lower Hb3748Y9.5-10.5 g/dl10.0 (0.60)10.7 (1.00)155 (15)NA82 (9.0)NA165 (50)160 (NA)−5.1
(iv) LVDc / higher Hb3948Y13-14 g/dl10.3 (0.60)12.8 (2.20)154 (18.5)NA84 (9.3)NA172 (36)166 (NA)−5.8
Hayashi (2000)Am J Kidney DisPartial Hct correctionb916N30%7.9 (0.5)c10.7 (0.6)c147.8 (23.1)151.3(22.8)74.2 (14.70)76.5(7.8)141 (36)127 (30)−13.7
London (2001)J Am Soc NephrolTreated15354 (37)dY10-11 g/dl8.7 (1.70)10.5 (1.50)169.4 (29.7)146.7 (29)90.2 (15.60)78 (14)174 (45)162 (45)−12
Sikole (2002)Artificial OrgansTreated1452Y30-35%7.9 (1.40)10.0 (1.00)NAeNAeNAgNAg172 (29)129 (26)−43.4
Frank (2004)Kidney IntTreated2328Y12.5 g/dl10.5 (0.90)13.4 (3.10)132 (4)128 (3)76 (2)73 (2)134 (26)97 (25)−37
Roger (2004)J Am Soc Nephrol(i) Lower Hb78104Mixedf9-10 g/dl11.2 (0.80)10.8 (1.30)137 (18)133 (20)81 (10)77 (11)101 (23)105 (24)4
(ii) Higher Hb74104Mixedf12-13 g/dl11.2 (0.90)12.1 (1.40)139 (19)138 (23)80 (11)79 (12)105 (23)107 (25)2
Ayus (2005)Kidney IntTreated4026N12 g/dl9.1 (0.70)11.3 (1.90)148 (21)146 (18)82 (11)81 (9)157 (56)142 (56)−15
Hampl (2005)Kidney Blood Press ResTreated230229Y13.5-14.5 g/dl11.2 (2.20)14.1 (1.40)165 (8)130 (10)92 (8)80 (5)159 (50.4)130.2 (42.7)−28.8
Levin (2005)Am J Kidney Dis(i) Lower Hb74104Mixedf9-10.5 g/dl11.7 (0.80)11.4 (NA)140.5(18.6)133.4 (NA)79.6 (10.50)75.1 (NA)98 (25)104 (NA)5.2
(ii) Higher Hb78104Mixedf12-14 g/dl11.8 (0.80)12.7 (NA)137.1(17.5)133.9 (NA)75.8 (11.50)75.6 (NA)101 (22)101 (NA)0.4
Parfrey (2005)J Am Soc Nephrol(i) Lower Hb30096Y9.5-11.5 g/dl11.0 (1.20)10.9 (1.20)140 (20)139 (22)80 (12)79 (14)112 (33)128 (40)16.3
(ii) Higher Hb29696Y13.5-14.5 g/dl11.0 (1.20)13.3 (1.50)144 (21.65)141 (22.14)81 (11.48)80 (12.57)117 (36)128 (43)11.8
Ritz (2007)Am J Kidney Dis(i) Lower Hb8260Mixedf10.5-11.5 g/dl11.712.1 (NA)133 (NA)134 (NA)80 (NA)80 (NA)116 (35)117 (36)0.5
(ii) Higher Hb8860Mixedf13-15 g/dl11.913.5 (NA)134 (NA)134 (NA)78 (NA)76 (NA)114 (31)112 (33)−1.2
  • Y, yes; N, no; CLVH, concentric left ventricular hypertrophy; LVD, left ventricular dilation.

  • a Reporting only for cohorts treated with EPO.

  • b Same study cohort evaluated at two targets. Only the results for partial-correction are reported here.

  • c Hematocrit has been converted to hemoglobin by dividing by 3.

  • d By patient, mean (SD).

  • e Mean arterial pressure increased from 114.7 ± 13.9 at baseline to 119.3 ± 13.8 mmHg at end of treatment period (where mean arterial pressure = diastolic arterial pressure + [systolic arterial pressure + diastolic arterial pressure]/3).

  • f These cohorts are classified as CKD for the purpose of this analysis. The following are numbers of patients who commenced dialysis during the study period: 15 out of 78, Roger 2004 (i); 24 out of 74, Roger 2004 (ii); 8 out of 74, Levin 2005 (i); 11 out of 78, Levin 2005 (ii); 3 out of 82, Ritz 2007 (i); and 2 out of 88, Ritz 2007 (ii).